Benjamin Braun, MD, PhD

Education

Princeton University, A.B., 1990, Molecular Biology
University of California, Los Angeles, Ph.D., 1998, Molecular Biology
University of California, Los Angeles, M.D., 1998, Medicine
University of California, San Francisco, Resident, 1998-2000, Pediatrics
University of California, San Francisco, Fellow, 2000-2003, Hematology/Oncology

Honors & Awards

• 1990
  Cum Laude, Princeton University
• 1990
  Phi Beta Kappa
• 1990
  Medical Scientist Training Program Fellowship, University of California, Los Angeles
• 2000-2003
  Campini Fellowship, University of California, San Francisco
• 2004
  David G. Nathan Award, Society for Pediatric Research
• 2004
  Melvin Grumbach Pediatric Research Award, UCSF
• 2005
  Basic Research Scholar American Society of Hematology
• 2010
  Fellows' Leadership and Advocacy Group FacultyLeadership Award, Department of Pediatrics, UCSF

Selected Publications

1. Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.  View on PubMed
2. Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, Tuveson DA, Braun BS, Shannon K KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.  View on PubMed
3. Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.  View on PubMed
4. Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.  View on PubMed
5. Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM Tissue-Specific Oncogenic Activity of KRASA146T.  View on PubMed
6. Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.  View on PubMed
7. Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.  View on PubMed
8. Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.  View on PubMed
9. Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.  View on PubMed
10. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.  View on PubMed
11. Braun BS Traxtile: Interactive editing of cell tracks in time-lapse images.  View on PubMed
12. Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.  View on PubMed
13. Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.  View on PubMed
14. Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.  View on PubMed
15. Braun BS KIT's ship comes in.  View on PubMed
16. Ward AF, Braun BS, Shannon KM Targeting oncogenic Ras signaling in hematologic malignancies.  View on PubMed
17. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.  View on PubMed
18. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.  View on PubMed
19. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.  View on PubMed
20. Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.  View on PubMed

Go to UCSF Profiles, powered by CTSI